Cisplatin: From DNA damage to cancer chemotherapy

doi:10.1016/S0079-6603(01)67026-0

Progress in Nucleic Acid Research and Molecular Biology

Volume 67, 2001, Pages 93-130

https://doi.org/10.1016/S0079-6603(01)67026-0 Get rights and content

Abstract

Cisplatin [cis-DDP, cis-diamminedichloroplatinum(II)] is a potent anticancer drug that has been used successfully to treat tumors of the head, neck, lungs, and genitourinary tract. The biological activity of cisplatin was discovered serendipitously more than 30 years ago, and since that time research efforts have focused on elucidating its mechanism of action. The present review provides a historical perspective of our attempts to understand this complex phenomenon and the results of recent work that guides our current activities in this field. Continued efforts to understand the mechanism of genotoxicity of cisplatin are expected to lead to the discovery of new drugs and combinations for the improvement of cancer chemotherapy.

References (151)

B. Rosenberg et al.
J. Biol. Chem.
(1967)
D.J. Szalda et al.
J. Inorg. Biochem.
(1979)
R. Grosschedl et al.
Trends Genet.
(1994)
R.S. Farid et al.
Tox. Appl. Pharma.
(1996)
M.M. McA'Nulty et al.
Mutat. Res.
(1996)
M. Bustin et al.
Biochim. Biophys. Acta
(1990)
Z.S. Juo et al.
J. Mol. Biol.
(1996)
D.S. Pilch et al.
J. Mol. Biol.
(2000)
P.C. Billings et al.
Biochem. Biophys. Res. Commun.
(1992)
E.R. Jamieson et al.
J. Biol. Cheap.
(1999)

A. Gelasco et al.

Topics in Biological Inorganic Chemistry

D.B. Zamble et al.

Cisplatin-Chemistry and Biochemistry of a Leading Anticancer Drug

J. Zlatanova et al.

FASEB J.

(1998)

E.R. Jamieson et al.

Chem. Rev.

(1999)

B. Rosenberg et al.

Nature (London)

(1965)

B. Rosenberg et al.

Nature (London)

(1969)

B. Rosenberg et al.

Cancer Res.

(1970)

G.J. Bosl et al.

N. Engl. J. Med.

(1997)

J.K. Barton et al.

Metal Ions in Biology

K.G. Strothkamp et al.

S.J. Lippard et al.

Science

(1976)

K.W. Jennette et al.

J. Am. Chem. Soc.

(1976)

M. Howe-Grant et al.

Inorg. Synth.

(1980)

K.E. Erkkila et al.

Chem. Rev.

(1999)

G.L. Cohen et al.

Science

(1979)

H.M. Ushay et al.

Biochemistry

(1981)

G.L. Cohen et al.

J. Am. Chem. Soc.

(1980)

J.P. Caradonna et al.

J. Am. Chem. Soc.

(1982)

P.J.M. Van De Vaart et al.

Int. J. Cancer

(2000)

R.B. Cieearelli et al.

Biochemistry

(1985)

A.L. Pinto et al.

Y. Corda et al.

Biochemistry

(1991)

Y. Corda et al.

Biochemistry

(1993)

C. Cullinane et al.

Biochemistry

(1999)

J.A. Mello et al.

Biochemistry

(1995)

J.H. Toney et al.

S.L. Bruhn et al.

Nucleic Acids Res.

(1993)

P.M. Pil et al.

Science

(1992)

S.J. Brown et al.

Science

(1993)

Cited by (580)

Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells
2024, Translational Oncology
Ovarian cancer (OC), the second most common form of gynecologic malignancy, has a poor prognosis and is often discovered in the late stages. Platinum-based chemotherapy is the first line of therapy. Nevertheless, treatment OC has proven challenging due to toxicity and the development of acquired resistance to therapy. Tumor microenvironment (TME) has been associated with platinum chemoresistance.
Malignant ascites has been used as OC tumor microenvironment and its ability to induce platinum chemoresistance has been investigated.
Our results suggest that exposure to OC ascites induces platinum chemoresistance in 11 of 13 cases (85 %) on OC cells. In contrast, 75 % of cirrhotic ascites (3 of 4) failed to confer platinum chemoresistance to OC cells. Cytokine array analysis revealed that IL -6 and to a lesser extent HGF were enriched in OC ascites, whereas IL -22 was enriched in cirrhotic ascites. Pharmaceutical inhibitors targeting the IL -6/ JAK pathway were mildly effective in overcoming platinum chemoresistance induced by malignant ascites. In contrast, crizotinib, an HGF/c- MET inhibitor, and 2-hydroxyestradiol (2HE2) were effective in restoring platinum chemosensitivity to OC.
Our results demonstrate the importance of OC ascites in supporting platinum chemoresistance and the potential of combination therapy to restore chemosensitivity of OC cells.
Production and synthesis of a novel <sup>191</sup>Pt-labeled platinum complex and evaluation of its biodistribution in healthy mice
2024, Bioorganic and Medicinal Chemistry
We previously reported that our sugar-conjugated platinum complex (cis-dichloro [(2-fluoro-α-d-glucopylanosidyl) propane-1,3-diamine] platinum: FGC-Pt) has low toxicity and tumor growth inhibitory effect comparable to that of cisplatin. We focused on radioactive Pt isotopes in order to analyze the kinetics of FGC-Pt using gamma-ray imaging techniques, assuming that FGC-Pt could be used for chemotherapy in the future. Therefore, in this study, we aimed to develop a non-invasive method to analyze the biodistribution of FGC-Pt using ¹⁹¹Pt-labeled FGC-Pt ([¹⁹¹Pt]FGC-Pt).
¹⁹¹Pt was produced via the (n,2n) reaction induced by accelerator neutrons. [¹⁹¹Pt]FGC-Pt was prepared using two different methods. In the first method, [¹⁹¹Pt]FGC-Pt (method A) was obtained through the accelerator neutron irradiation of FGC-Pt. In the second method, [¹⁹¹Pt]FGC-Pt (method B) was synthesized using [¹⁹¹Pt]K₂PtCl₄, which was obtained by the accelerator neutron irradiation of K₂PtCl₄. Highly purified [¹⁹¹Pt]FGC-Pt was obtained using the latter method, which suggests that the synthetic method using a ¹⁹¹Pt-labeled platinum reagent is suitable for the radioactivation of platinum complexes.
We also aimed to investigate whether a significant correlation existed between the biodistribution of FGC-Pt and [¹⁹¹Pt]FGC-Pt in healthy mice 24 h after tail vein administration. FGC-Pt and [¹⁹¹Pt]FGC-Pt were similarly distributed in healthy mice, with a higher accumulation in the liver and kidney 24 h post injection. In addition, a significant correlation (p < 0.05, r = 0.92) between the ¹⁹¹Pt radioactivity concentration (%ID/g (gamma counter)) and platinum concentration (%ID/g (ICP-MS)) was observed in 13 organs. These results suggest that ¹⁹¹Pt-labeled compounds, synthesized using radioactive platinum reagents, can be used to confirm the biodistribution of platinum compounds. Our study on the biodistribution of [¹⁹¹Pt]FGC-Pt is expected to contribute to the development of novel platinum-based drugs in the future.
Cisplatin-induced DNA crosslinks trigger neurotoxicity in C. elegans
2024, Biochimica et Biophysica Acta - Molecular Cell Research
The anticancer drug cisplatin (CisPt) injures post-mitotic neuronal cells, leading to neuropathy. Furthermore, CisPt triggers cell death in replicating cells. Here, we aim to unravel the relevance of different types of CisPt-induced DNA lesions for evoking neurotoxicity. To this end, we comparatively analyzed wild-type and loss of function mutants of C. elegans lacking key players of specific DNA repair pathways. Deficiency in ercc-1, which is essential for nucleotide excision repair (NER) and interstrand crosslink (ICL) repair, revealed the most pronounced enhancement in CisPt-induced neurotoxicity with respect to the functionality of post-mitotic chemosensory AWA neurons, without inducing neuronal cell death. Potentiation of CisPt-triggered neurotoxicity in ercc-1 mutants was accompanied by complex alterations in both basal and CisPt-stimulated mRNA expression of genes involved in the regulation of neurotransmission, including cat-4, tph-1, mod-1, glr-1, unc-30 and eat-18. Moreover, xpf-1, csb-1, csb-1;xpc-1 and msh-6 mutants were significantly more sensitive to CisPt-induced neurotoxicity than the wild-type, whereas xpc-1, msh-2, brc-1 and dog-1 mutants did not distinguish from the wild-type. The majority of DNA repair mutants also revealed increased basal germline apoptosis, which was analyzed for control. Yet, only xpc-1, xpc-1;csb-1 and dog-1 mutants showed elevated apoptosis in the germline following CisPt treatment. To conclude, we provide evidence that neurotoxicity, including sensory neurotoxicity, is triggered by CisPt-induced DNA intra- and interstrand crosslinks that are subject of repair by NER and ICL repair. We hypothesize that especially ERCC1/XPF, CSB and MSH6-related DNA repair protects from chemotherapy-induced neuropathy in the context of CisPt-based anticancer therapy.
Novel ternary Pd(II) complexes as potent anticancer drugs for ovarian carcinoma treatment
2023, Journal of Molecular Structure
A novel straightforward method has been introduced to synthesize two new water soluble Pd complexes, [Pd(phd)(AA)]NO₃, (phd = 1,10-phenanthroline-5,6-dione; 1, AA = L-isoleucine and 2, AA = L-leucine) using water as a green solvent. Complexes 1 and 2 have been characterized by elemental analysis, FT-IR, ¹H NMR spectroscopy and mass spectrometry. A theoretical study of these complexes was conducted using ADME, DFT, and molecular docking. ADME data revealed these complexes as potentially anti-cancer drugs. Fluorescence, UV–Vis, and CD spectroscopy were applied to study the mechanism of DNA interaction. As a result of the fluorescence data, both complexes statically quenched DNA. Based on thermodynamic parameters, Pd(II) complexes and DNA interact via an electrostatic approach and groove binding. CD spectra indicated that both complexes exhibit a slight blue shift with a decrease in intensity across all bands. The experimental data were in agreement with DFT calculations and docking studies. In sum, the mode of binding with DNA intracellular structure is via groove binding and electrostatic interactions. Cytotoxic screening of these compounds carried out against the human ovarian carcinoma cell line A2780SP and cisplatin-resistant variant A2780CP revealed that both complexes showed significantly higher anticancer activity against A2780CP cancer cell line compared to cisplatin. Moreover, all theoretical and experimental data show that complex 2 is more active than complex 1.
Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy
2023, Journal of Controlled Release
Owing to the unique DNA damaging cytotoxicity, platinum (Pt)-based chemotherapy has long been the first-line choice for clinical oncology. Unfortunately, Pt drugs are restricted by the severe dose-dependent toxicity and drug resistance. Correspondingly, Pt(IV) prodrugs are developed with the aim to improve the antitumor performance of Pt drugs. However, as “free” molecules, Pt(IV) prodrugs are still subject to unsatisfactory in vivo destiny and antitumor efficacy. Recently, Pt(IV) prodrug nanotherapeutics, inheriting both the merits of Pt(IV) prodrugs and nanotherapeutics, have emerged and demonstrated the promise to address the underexploited dilemma of Pt-based cancer therapy. Herein, we summarize the latest fronts of emerging Pt(IV) prodrug nanotherapeutics. First, the basic outlines of Pt(IV) prodrug nanotherapeutics are overviewed. Afterwards, how versatile Pt(IV) prodrug nanotherapeutics overcome the multiple biological barriers of antitumor drug delivery is introduced in detail. Moreover, advanced combination therapies based on multimodal Pt(IV) prodrug nanotherapeutics are discussed with special emphasis on the synergistic mechanisms. Finally, prospects and challenges of Pt(IV) prodrug nanotherapeutics for future clinical translation are spotlighted.
A novel use of an oxime molecule as supramolecular tecton. Synthesis of a Pt (II) 2D network
2023, Journal of Molecular Structure
To test the hypothesis that we could use the 4-pyridiniumcarboxaldehyde oxime (4-HoxpyH) coordinated through the oxime N atom to organize Pt(II) compounds via charge-assisted [>N–H] ⁺···[Cl₂Pt]^– hydrogen bonds, we synthesized and determined the crystal structure of the compound [PtCl₃(4-HoxpyH)], 1. The structure of 1 shows that the ligand HoxpyH coordinates through the nitrogen atom of the oxime group and forms the expected H-bonds. In the crystal, six molecules interact through hydrogen bonds and O···Cl interactions, forming rings that extend into two-dimensional structures. These 2D structures are stacked on top of each other through Pt···pyH and Pt–Cl···pyH interactions, without interpenetrating or forming channels.

View all citing articles on Scopus

View full text

Cisplatin: From DNA damage to cancer chemotherapy

Abstract

J. Biol. Chem.

J. Inorg. Biochem.

Trends Genet.

Tox. Appl. Pharma.

Mutat. Res.

Biochim. Biophys. Acta

J. Mol. Biol.

J. Mol. Biol.

Biochem. Biophys. Res. Commun.

J. Biol. Cheap.

Cell (Cambridge, Mass.)

Cell (Cambridge, Mass.)

Cell (Cambridge, Mass.)

Cell (Cambridge, Mass.)

Cell, (Cambridge, Mass.)

Eur. J. Cancer

Science

Chem. Rev.

Chem. Rev.

Chem. Rev.

Topics in Biological Inorganic Chemistry

Cisplatin-Chemistry and Biochemistry of a Leading Anticancer Drug

FASEB J.

Chem. Rev.

Nature (London)

Nature (London)

Cancer Res.

N. Engl. J. Med.

Metal Ions in Biology

Science

J. Am. Chem. Soc.

Inorg. Synth.

Chem. Rev.

Science

Biochemistry

J. Am. Chem. Soc.

J. Am. Chem. Soc.

Int. J. Cancer

Biochemistry

Biochemistry

Biochemistry

Biochemistry

Biochemistry

Nucleic Acids Res.

Science

Science